Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab

Antonio J. Vallejo-Vaz, Lawrence A. Leiter, Stefano Del Prato, Marja-Riitta Taskinen, Dirk Mueller-Wieland, Maja Bujas-Bobanovic, Alexia Letierce, Jonas Mandel, Rita Samuel, Kausik K. Ray

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalEuropean journal of preventive cardiology
Volume27
Issue number15
Pages (from-to)1663-1674
Number of pages12
ISSN2047-4873
DOIs
Publication statusPublished - Oct 2020
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Alirocumab
  • proprotein convertase subtilisin
  • kexin type 9
  • non-high-density lipoprotein cholesterol
  • low-density lipoprotein cholesterol
  • triglycerides
  • goal attainment
  • CARDIOVASCULAR-RISK PATIENTS
  • NON-HDL CHOLESTEROL
  • REMNANT CHOLESTEROL
  • INHIBITOR ALIROCUMAB
  • RESIDUAL RISK
  • EFFICACY
  • SAFETY
  • DISEASE
  • HYPERCHOLESTEROLEMIA
  • EZETIMIBE
  • 3121 Internal medicine

Cite this